Estrella Immunopharma, Inc. (ESLA) Stock Price & Analysis

Estrella Immunopharma, Inc. (ESLA) rose 1.77% to USD 1.15 as of June 10, 2026 at 11:18 UTC, according to Nexqual real-time market data.

ESLA last closed at USD 1.13; the session ranged USD 1.04–1.21 on volume of 39,642 shares. Market capitalization is $49.49M, with a 52-week range of USD 0.78–3.15 (NCM). Source: Nexqual, June 10, 2026 at 11:18 UTC.

Key Statistics (as of June 10, 2026 at 11:18 UTC)

Technical Analysis (ESLA)

Nexqual's technical model rates ESLA "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 11:18 UTC.

Analyst Ratings (ESLA)

Wall Street analysts rate ESLA "None" based on 1 analysts, with a mean price target of USD 12 (range USD 12–12), per Nexqual as of June 10, 2026 at 11:18 UTC.

Earnings (ESLA)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 11:18 UTC.

Financials & Fundamentals (ESLA)

Source: Nexqual, June 10, 2026 at 11:18 UTC.

Financial Health Score (ESLA)

Nexqual rates Estrella Immunopharma, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 11:18 UTC.

Ownership (ESLA)

Source: Nexqual, June 10, 2026 at 11:18 UTC.

Leadership (ESLA)

Estrella Immunopharma, Inc. is led by Cheng Liu (age 58), CEO, President & Director, per Nexqual as of June 10, 2026 at 11:18 UTC.

Major Backers & Investors (ESLA)

Notable institutional backers of Estrella Immunopharma, Inc. include Armistice Capital, LLC, Wells Fargo & Company, Fidelity, according to Nexqual as of June 10, 2026 at 11:18 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 11:18 UTC.

From Estrella Immunopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)

Key Strengths & Strategy (as disclosed to the SEC)

• Our EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).   Our Technology Platform: The ARTEMIS® T-Cell Receptor System   We hold an exclusive license from Eureka Therapeutics ("Eureka") to utilize the proprietary ARTEMIS® Cell Receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies.
• The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs.   13     Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA.
• Currently approved therapies, such as Kymriah® (Novartis) and Yescarta® (Kite Pharma), have demonstrated efficacy in relapsed or refractory B-cell malignancies but face limitations due to:         3     Our Approach: EB103 aims to address these challenges by enhancing safety, scalability, and accessibility.
• Our streamlined production process also enables us to lower the cost of manufacturing.   Opportunities for Increasing Total Accessible Market (TAM) for Blood Cancers with a Best-in-Class CD19 T-cell Therapy   Hematological Cancers   Hematological cancers, or blood cancers, are cancers that begin in blood-forming tissues, such as the bone marrow, or in the body's immune cells.

Partnerships

• With the dosing of the first patient in July 2024 in the STARLIGHT-1 clinical trial, the development milestone pursuant to Section 8.2.1 (First Patient Dosed in the First Clinical Trial of a Licensed Product) in the Licensing Agreement with Eureka was met.
• We believe that, in collaboration with Imugene and Imugene's product candidate, CF33-CD19t, an oncolytic virus, EB103 T-cells have the potential to overcome this barrier using a "mark and kill" strategy.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:18 UTC. This page is informational and not investment advice.